Business Description
![LeMaitre Vascular Inc LeMaitre Vascular Inc logo](https://static.gurufocus.com/logos/0C00000L0G.png?14)
LeMaitre Vascular Inc
NAICS : 339112
SIC : 3841
ISIN : US5255582018
Share Class Description:
STU:LHU: Ordinary SharesDescription
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products areĀ used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards theĀ proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.74 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 0.36 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 25.93 | |||||
Beneish M-Score | -2.43 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11 | |||||
3-Year EBITDA Growth Rate | 6.5 | |||||
3-Year EPS without NRI Growth Rate | 9.9 | |||||
3-Year FCF Growth Rate | -5.4 | |||||
3-Year Book Growth Rate | 16.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 18.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 14.4 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47 | |||||
9-Day RSI | 52.76 | |||||
14-Day RSI | 56.47 | |||||
6-1 Month Momentum % | 39.42 | |||||
12-1 Month Momentum % | 17.89 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.57 | |||||
Quick Ratio | 5.54 | |||||
Cash Ratio | 4.04 | |||||
Days Inventory | 278.76 | |||||
Days Sales Outstanding | 47.82 | |||||
Days Payable | 19.69 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.74 | |||||
Dividend Payout Ratio | 0.39 | |||||
3-Year Dividend Growth Rate | 13.8 | |||||
Forward Dividend Yield % | 0.8 | |||||
5-Year Yield-on-Cost % | 1.46 | |||||
3-Year Average Share Buyback Ratio | -2.8 | |||||
Shareholder Yield % | 0.66 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 66.45 | |||||
Operating Margin % | 20.46 | |||||
Net Margin % | 16.99 | |||||
FCF Margin % | 16.55 | |||||
ROE % | 11.68 | |||||
ROA % | 10.13 | |||||
ROIC % | 14.62 | |||||
ROC (Joel Greenblatt) % | 42.92 | |||||
ROCE % | 14.01 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 53.35 | |||||
Forward PE Ratio | 44.98 | |||||
PE Ratio without NRI | 53.53 | |||||
Shiller PE Ratio | 75.75 | |||||
Price-to-Owner-Earnings | 66.91 | |||||
PEG Ratio | 7.65 | |||||
PS Ratio | 9.06 | |||||
PB Ratio | 5.86 | |||||
Price-to-Tangible-Book | 8.94 | |||||
Price-to-Free-Cash-Flow | 54.8 | |||||
Price-to-Operating-Cash-Flow | 45.8 | |||||
EV-to-EBIT | 39.82 | |||||
EV-to-EBITDA | 32.61 | |||||
EV-to-Forward-EBITDA | 29.11 | |||||
EV-to-Revenue | 8.6 | |||||
EV-to-Forward-Revenue | 7.98 | |||||
EV-to-FCF | 52.03 | |||||
Price-to-Projected-FCF | 3.27 | |||||
Price-to-DCF (Earnings Based) | 1.79 | |||||
Price-to-DCF (FCF Based) | 1.75 | |||||
Price-to-Median-PS-Value | 1.49 | |||||
Price-to-Peter-Lynch-Fair-Value | 8.09 | |||||
Price-to-Graham-Number | 4.61 | |||||
Price-to-Net-Current-Asset-Value | 11.48 | |||||
Price-to-Net-Cash | 28.76 | |||||
Earnings Yield (Greenblatt) % | 2.51 | |||||
FCF Yield % | 1.83 | |||||
Forward Rate of Return (Yacktman) % | 8.03 |